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Abstract
Veterinary pharmaceuticals include a wide range of anti-infectives and addi-
tives in the use for animal health, nutrition, reproduction, and productivity. 
Antimicrobials are among the most extensively used drugs in developing countries 
largely due to large population of livestock and the burden of infectious diseases. 
The introduction of penicillin in 1943 and other antibiotics thereafter provided 
remedies for many infections in humans and animals, reducing mortality and pro-
ductivity losses. Since then, a repertoire of antibiotics and antimicrobials has been 
introduced as chemotherapeutics and/or prophylaxis. This success notwithstanding, 
many pathogens of consequences are no longer susceptible owing to emergence of 
antimicrobial-resistant (AMR) microorganisms. This has made treatment of infec-
tious diseases less effective. Beside spontaneous emergence of mutant microorgan-
isms, scientists are wary of AMR caused by intensive use of antibiotics in humans 
and animals, sometimes in subtherapeutic doses as preventive medicine. In devel-
oping countries, environmental exposure and persistent use of antibiotics in food 
animals may leave residues in the food chain. The consequences include develop-
ment of AMR. In this chapter, we reviewed antimicrobial use in veterinary medicine 
and sequela in the emergence of AMR and described the imperative of antimicrobial 
stewardship in veterinary practice to combat AMR in developing countries.
Keywords: veterinary drugs, antimicrobial resistance, stewardship,  
developing countries
1. Introduction: veterinary pharmaceuticals and antimicrobials
Veterinary pharmaceuticals include drugs, medications, and other substances in 
use to treat or prevent animal diseases for health, growth promotion, and productiv-
ity [1]. These drugs can be broadly divided into categories according to the different 
pathogens or targeted infections. They include antiparasitic drugs, antiinflammatory, 
reproductive medication, surgical medications, anesthetics, nutritional drugs, and 
feed additives sometimes used as growth promoters (Table 1). Among commonly 
used drug in veterinary medicine are antibiotics. These drugs and medicaments 
can be administered in form of injectable, tablet, bolus, drench, and bath/wash or 
added to feed and drinking water. There are documented evidence of earlier norms 
and practices of animal husbandry regarding how shepherd and nomads provide 
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medication for livestock. Some were written document by priests in monasteries, such 
as the use of garlic (Allium sativum L.) and ointment made from honey and grease 
[2]. This is similar to what has now been recognized in modern veterinary medicine as 
ethno-veterinary or alternative medicine in human and according to the World Health 
Organization (WHO); 75% of the world’s population are using herbs for basic health-
care [3]. Such practices predate modern day pharmacopeia, which has, however, 
refined and synthesized the delivery of veterinary and human medicines. Some global 
industrial leaders in modern veterinary pharmaceuticals include Zoetis (formerly 
Pfizer Animal Health), Merck, Bayer, Elanco Animal Health, Boehringer Ingelheim 
Animal Health (Merial), Norvatis Animal Health, and many others. These companies 
and their subsidiaries are engaged in the multibillion dollars profitable business of 
drug distribution in developing countries (and also from Asia to Africa) in millions of 
doses some of which may be overused and contributing to drug resistance [4, 5].
Antibiotics Antiparasitic Antiinflammatory Anesthetics Growth 
promoters
Terramycin Banminth Ibuprofen Phenobarbital Feed grade 
antibiotics
Penicillin Ivermectin Meloxicam Thiamylal Probiotics
Streptomycin Diminazene 
aceturate
Dexamethasone Xylazine 
hydrochloride
Dihydropyridine
Colistin Amprolium Prednisone Chlorpromazine Organic acids
Erythromycin Piperazine Prednisolone Diazepam Amino acids
Doxycycline Albendazole Aspirin Thiopental 
sodium
Racto-amine
Enrofloxacin Closantel Phenylbutazone Pentobarbital Sodium-
bicarbonate
Tylosin Dermatocide Dimethylsulfoxide Chloral hydrate Potassium 
chloride
Oxytetracycline Diazinon Flunixin Methohexital Fatty acids
Amoxycillin Nitroxynil Meglumine Methoxyflurane Zytomil
Gentamycin Cypermethrin Cortisone Halothane Renature-Z oral 
powder
Chloramphenicol Pyrantel 
pamoate
Methimazole Diethyl ether Vita-Sel-E oral 
solution
Ciprofloxacin Praziquantel Celecoxib Isoflurane Eucament plus 
oral solution
Griseofulvin Mectizan Colchicine Enflurane Chicktonic
Norfloxacin Nitroxyl Cyclooxygenase Nitrous oxide Aminogrow WS
Rifampin Diclazuril Pylorus Glyceryl 
quiacolate
Electromix WS
Novidium 
chloride
Mavacoxib Succinyl choline Introvit A+ WS
Isomethadone Tepoxalin Curare Introvit-ES-200 
WS
Furazolidone Homidium 
chloride
Piroxicam Lidocaine Introvit-K-200 
WS
Source: survey of commonly use veterinary antimicrobials in Nigeria, courtesy of Dr. Jolly Amoche of National 
Veterinary Research Institute, Vom.
Table 1. 
Some veterinary pharmaceuticals distributed in Nigeria.
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Globally, there are more livestock in the world than human, with livestock 
systems occupying about 30% of the planet’s ice-free terrestrial surface area [6]. 
Most of these animals are kept in free range husbandry systems in under-developed 
countries where the enterprise supports the livelihood of about 600 million small 
holders [7]. The livestock sector in developing countries is also evolving in response 
to rapidly increasing demand for livestock products with changes in the demand for 
livestock products being driven among other factors by human population growth, 
urbanization, and increasing income [8, 9].
A major limiting factor in profitable livestock production in developing 
country is the burden of infectious diseases. These livestock diseases cause great 
socioeconomic impact, and the burdens are most of the time exasperated by poor 
biosecurity in both intensive and open production systems. This has made the use 
of antimicrobials for treatment of diseases indispensable [10]. It is important to 
emphasize that the reduction in the burden of infectious livestock diseases has been 
possible due in part to the use of a wide range effective drugs and vaccines and 
improvements in diagnostic techniques and services [11].
Therapeutic treatments are targeted at animals that are diseased. In food ani-
mals, it is usually often more convenient to treat entire groups by administering 
medication through feed or water, though individual animals may also be treated. 
For animals like poultry and fish, mass medication is the most feasible means 
of treatment but with the possibility of drug dispersal into the environment via 
leaching and agricultural wastewater [12]. Furthermore, certain mass-medication 
procedures called metaphylaxis, aimed at treatment of sick animals while medicat-
ing others in the group that may not be sick but exposed, can also be counterpro-
ductive. Other prophylactic antimicrobial treatments are typically used during 
high-risk periods for infectious diseases even, while the animals may not be infected 
also described as nonspecific infection prevention [13]. These practices, however 
plausible, are currently considered as contributing to emergence of antimicrobial 
resistance due to subtherapeutic exposure to veterinary pharmaceuticals by both 
infected and noninfected animals, as well as the environment [14].
Antimicrobial resistance has been described as the ability of bacterial, para-
sites, viruses, and fungi to survive and spread despite treatment with specific and 
combination therapy that are normally used against them [15]. The World Health 
Organization also emphasized that resistance happens when microorganisms change 
when they are exposed to antimicrobial drugs (such as antibiotics, antifungals, 
antivirals, antimalarials, and antihelmintics). These microorganisms that develop 
antimicrobial resistance are sometimes referred to as “superbugs”. Antimicrobial 
resistance may be spontaneous and occur as a natural process, and resistance to 
antimicrobials dates back as far as when the first generations of antibiotics includ-
ing penicillin were introduced in 1943/44 by Alexander Fleming [13]. In evolution, 
selection pressure is bound to cause subpopulation of microorganism with resistance 
genes to emerge [16]. This selective pressure has been ascribed to appropriate and 
inappropriate use of antimicrobials but aggravated by (1) intensity of usage, (2) per-
sistence of usage, (3) under usage and subtherapeutic doses that animals are exposed 
to in prophylactic treatment, and (4) unintended human exposure through antimi-
crobials in food residues and the environment [10].
The burden of infectious diseases in developing countries and intensive use of 
antimicrobials to combat this has also been stressed in a study that suggested that 
up to a third of the global increase (67%) in antibiotic consumption will be in food 
animals, over the period 2010–2030 and attributable to low-middle income coun-
tries [17]. This challenge is in view of the high burden of foodborne infectious and 
zoonotic diseases especially also in developing countries [18]. Veterinary practices 
use drugs for mitigating these diseases in animals, including food animals that 
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have to be maintained in health and productivity (meat, egg, and milk). To prevent 
these drugs from getting into the food chain and being consumed by humans, 
“withdrawal time,” which is the last time any drug may be administered before 
egg/milk and meat from such animals are collected and consumed is specified. The 
withdrawal time for antimicrobials is intended to prevent harmful drug residues 
in meat, milk, and eggs [19]. These waiting periods need to be observed from the 
time of treatment to when the animals are slaughtered for food. This is important 
because food products that contain antimicrobial residues not metabolized leaves 
residues beyond permissible limits at the end of the withdrawal period may be 
considered unwholesome for consumption and may contribute to antimicrobial 
resistance in humans [20].
Veterinary pharmaceuticals, therefore, contribute in many ways to the emer-
gence of antimicrobial resistance either directly in suboptimal usage in animals or 
indirectly in human who consume subtherapeutic doses in animal products [13]. 
When resistant organism emerges, it has also been argued that human sources also 
seed these resistant bacteria to animals and the environment through sewage [21]. 
A recent study by Marcelino et al. [22] described high levels of antibiotic resistance 
gene expression among birds living in a wastewater treatment plants. The study 
observed that birds feeding at a wastewater treatment plant carried greatest resis-
tance gene burden, suggesting that human waste, even after treatment, contributes 
to the spread of antibiotic resistance genes to the wild. Domestic and wild animals, 
including rodents, and birds, can acquire these environmental contaminants and 
pass them on via their excreta to grazing land or feed of food animals, which may in 
turn end up in human through the food chain [23]. While it is imperative to canvass 
AMR stewardship through rational and circumspect usage of antimicrobial in 
animals, it is important to bear in mind that human also present risk to animals. The 
USFD described the phenomenon of antimicrobial resistance as a very complex and 
nonvictimless phenomenon, affecting both human and animal health [13].
2. Livestock diseases and the application of veterinary pharmaceuticals
In the management of infectious and noninfectious diseases of livestock in 
developing countries, a number of veterinary pharmaceuticals are administered. The 
choice of drugs is often determined by efficacy, availability, and cost. These factors 
are explored by manufacturers mostly based in developed countries from where the 
drugs are exported to developing countries. This distribution chain is also largely 
driven by business interest such that drug companies sell volumes that are targeted at 
frequent, intensive usage that may have deleterious effect such as emergence of AMR.
Intensive use of veterinary chemotherapy on the other hand may be justifiable 
considering that many bacterial, viral, and parasitic diseases like mycoplasmosis, 
Newcastle disease, avian influenza, anthrax, coccidiosis, brucellosis, foot and 
mouth disease (FMD), rift valley fever, etc. threatens socioeconomics, instills fear 
that shock systems, either by suddenly and rapidly killing large number of animals 
or causes large-scale drop in demand through fear of zoonotic diseases [24, 25]. On 
the other hand, the growing concern that animals are major sources of human dis-
eases and that around 60% of all animal diseases are zoonotic [26] make treatment 
of such diseases in animals an essential control measure before it is transmitted to 
human, and to reduce their capacity to cause epidemics and pandemics.
The livability and economic impacts of animal disease disaster is well documented, 
for instance, highly pathogenic avian influenza recently killed millions of poultry 
birds in Nigeria (including other countries in West Africa) and wiped out entire farms 
[27]. The costs of epidemic African swine fever in Cote d’Ivoire was estimated at 
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$9.2 million; Nipah virus in Malaysia $114 million, while contagious bovine pleuro-
pneumonia in Botswana costs about $300 million [25]. In the absence of preventive 
measures such as biosecurity and vaccination, the use of antimicrobial especially for 
nonviral infections is essential for profitable livestock production and to prevent infec-
tions that may be transmitted from animals to human as attested to by WHO [28].
3. Development of AMR in veterinary practice
The global antimicrobial resistance (AMR) crisis is predicted to kill roughly 
10 million people annually by 2050 due to antibiotic-resistant infections, with 
Africa alone accounting for about 4.15 million [29]. This is estimated to cost the 
global economy about $100 trillion [30] with about 28.3 million people pushed into 
extreme poverty [31]. The alarming rate of AMR in developing countries can be 
attributed to gross misuse of antimicrobials in human and animals [32]. Although 
resistance can still develop even at an appropriate antimicrobial use, however the 
situation can be made worse whenever there is excessive and unnecessary usage 
[33]. The global revolution in livestock and aquaculture is an underlying factor for 
frequent antimicrobial use and subsequent development of AMR. This is also driven 
by population increase, urbanization, improving economic conditions, and global-
ization. Countries like Brazil, China, and India are currently the hotspots for live-
stock intensification, while Nigeria, Myanmar, Peru, and Vietnam are future spots 
(Van [17]). In developing countries, most nonhuman-medical use of antimicrobials 
is almost certainly in livestock and farmed fish production and it is likely that most 
veterinary use is in intensive production rather than pastoralist or small-holder 
systems [34]. In Nigeria and other developing countries in sub-Saharan Africa, Asia 
and Middle East, there is paucity of information on antimicrobial drug resistance in 
farm animals, although little information exists on residue level [35–38]. However, 
there is information on antimicrobial drug resistant microbes isolated from human 
patients from different parts of Nigeria [39, 40]. Previous report by Adesokan et al. 
[41] on pattern of antimicrobial usage in livestock production in three states of 
South-Western Nigeria between the period of 2010 and 2012 showed an increased 
use of tetracyclines (33.6%) followed by fluoroquinolones (26.5%) and beta-
lactams/aminoglycosides (20.4%). Similar trend was also reported in Africa for 
tetracycline & beta-lactams [42]. However, studies by Idowu et al. [35] showed level 
of tetracycline residues between the ranges of 0.1–1.0% in chicken eggs.
The process of AMR development is very complex, and all of the factors that 
contributed to the events are not fully understood. It is clear that genetic change or 
mutation in microbial DNA may often cause resistance to antimicrobial agents, and 
this change might also be passed to the offspring or transferred to other related or 
even unrelated microorganisms [43]. This is known as “selection pressure” where 
the use of antimicrobial drugs in health care, agriculture, or industrial settings 
favor the survival of resistant strains (or genes) over susceptible ones, thus leading 
to a relative increase in resistant bacteria within microbial communities [44]. This 
is because no matter how effective an antimicrobial is, it rarely kills 100% of the 
organisms, meaning some may still survive due to genetic change, which can be 
passed forward. Currently, science has not fully proved the causes of different types 
of AMR that are causing great public health risks. The widespread use of antimi-
crobials in food production system especially in food-producing animals is another 
cause of AMR [45]. The extensive use of antimicrobials in animal production as 
growth promoters widely exposes the microbes to the drugs, thus enhancing the 
development of microbial resistance causing health consequences in both animals 
and humans. However, the scientific evidence of how and to what extent such drug 
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exposure affects human health still remains unclear. It is interesting to note that 
antimicrobial resistance would not develop in animals if antimicrobial drugs were 
never used in them [12].
There is danger to public health if resistant organism from animals can also cause 
disease in human exposed by a way of food consumption or direct contact with 
food-producing animals, companion animals, or through environmental spread 
[46]. The threat to public health also exists even if the organisms do not cause 
disease in human, because they may still be able to transfer the resistant genes from 
food-producing animals to unrelated human pathogenic bacteria as well as normal 
commensals [47]. It is then clear that the increase use of antimicrobials in animal 
production for variety of purposes such as for therapeutic and nontherapeutic use 
has contributed to increasing AMR in bacteria affecting man and animals [48]. In 
Africa and other developing countries, studies have suggested a strong correlation 
between the use of antimicrobials in veterinary practice and the development of 
AMR [49], because it is shown that a larger proportion of antimicrobial medica-
tions have been used in animals than humans mainly for food production purposes 
[50]. There is presence of high antimicrobial residue in meat and milk meant for 
human consumption correlating with the detection of multidrug resistance (MDR) 
bacteria in animals and their products [51] as well as in humans in contact with the 
animals [52–54]. This is also because a large proportion of the population in develop-
ing countries lives in close proximity with livestock, which enhance the chances of 
transfer of resistant microorganisms from animals to humans [55, 56]. Similarly, 
the increasing use of antimicrobials as prophylaxis in aquaculture in developing 
countries further contributed to the emergence of AMR causing problems in human, 
animal, and environmental health [57]. The risk to humans further exists especially 
when similar antimicrobial is used in both animals and humans, or there is presence 
of cross resistance between antimicrobial used in human and veterinary practice. 
Using antimicrobials that are also used in human medicine for growth promotion 
is especially conducive to AMR because exposure of many animals to low dosages 
makes resistance more likely to emerge [34].
For some antimicrobials, there is development of resistance by bacteria 
through plasmid-mediated transferable resistance [58]. The minimum inhibi-
tory concentrations (MIC) for a target pathogen might be considerably different 
from those of commensals, and thus, the resistance gene in commensals may 
be selected and transferred to humans and then to human pathogens leading to 
development of AMR [59]. Despite the fact that the exchange of genetic materi-
als and the short generation time of organism contributed to the development of 
AMR by many bacteria [60], some drugs such as penicillin still retains excellent 
activity on certain organism (e.g., Streptococcus agalactiae) after about 6 decades 
of usage [61].
AMR development can often be caused by inhibition of specific antimicrobial 
pathways such as cell wall synthesis, nucleic acid synthesis, ribosome function, 
protein synthesis, foliate metabolism, and cell membrane function by the organ-
ism [62–64]. The various steps involved in the production, distribution, prescrip-
tion, dispensing, and finally consumption of the drug by human patient or its use 
in animal production often contributed to the emergence of AMR especially when 
there is imprudent or irresponsible practice along the supply chain [65]. Part of 
veterinary medical education is to understand how antimicrobials affect micro-
organisms, and how they can be used responsibly to protect human and animal 
health [66]. In food production systems, veterinarians are on the frontline when 
it comes to keeping nation’s food supply safe. Advances in animal health care and 
management have greatly improved food safety over the years and have reduced 
the need for antimicrobials in food production systems [67]. Nevertheless, 
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antimicrobials are an important part of the veterinarian’s toolkit, and so veteri-
narians are aware that they should be used judiciously and in the best interest 
of animal and public health [66]. More importantly in the development of AMR 
is the quality of antimicrobials. Though difficult to implement, it has been sug-
gested that incidence of microbial resistance can be reduced if the antimicrobials 
that are used in human health are not used in veterinary practice [68]. Moreover, 
the practices of mass treatment of all animals in a group when only one animal is 
sick (metaphylaxis) as well as the treatment of all animals when they are exposed 
to conditions that can make them likely to be ill (prophylaxis) will result in an 
increased antimicrobial use and as such would encourage the development of 
resistance [69].
Although the development of animal-related AMR is associated with the quality 
and quantity of antimicrobial usage in veterinary practice, there are other underlin-
ing factors that can influence AMR development:
• Lack of awareness: in developing countries, there is little or no awareness or 
concern in the use of antimicrobials as compared to developed nations who 
recognize AMR as a global challenge. Omulo et al. [70] showed that only 24% 
of studies in Africa are related to AMR in animals or their products. In East 
Africa for example, despite the relevance of antibiotic procurement in health 
budgets, there was still a slow progress in research focusing on AMR of enteric 
pathogens. There is still lack of awareness among many veterinarians and other 
food producing personnel on the negative impact to human health as a result of 
extensive use of antimicrobials in animals [71].
• Lack of information: the information is lacking in developing countries con-
cerning the existence and prevalence of AMR in animals and animal products 
and the negative health consequence as well as the cost of AMR illness in 
people and animals.
• Fake and substandard drugs: there is much concern over counterfeits and 
substandard drugs in animal health care, but there is insufficient data to 
understand its importance. Counterfeits and substandard products, which 
contain active ingredient at a lower level, will increase the chance of develop-
ing resistance. There is no comprehensive information on fake/substandard 
veterinary drugs.
• Lack of adequate ‘One Health’ integration between animal and human health-
care: in developing countries, there is poor collaboration in healthcare sectors 
between human and veterinary practice especially on collection and sharing of 
data on antimicrobial usage. However, at international level, good collabora-
tion exists in the area of AMR between human and animal world health bodies 
like WHO, OIE, and FAO.
• Lack of substitution to the use of antimicrobials: alternative to the use of 
antimicrobials is lacking in developing countries unlike the developed nations 
that had successfully banned the use of antimicrobials as growth promoters 
and replaced with alternative growth promoters and good practice without 
having negative impact on the performance of their livestock industries. This 
could hardly be achieved in developing nations that have propensity to source 
antimicrobials from the black markets, which may be of poor quality, thus 
exacerbating the problem and creating a considerable increase in disease, with 
consequent mortality and morbidity losses [34].
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4. Prevention of AMR in veterinary practice
In a bid to ensure measurable containment of AMR, there is a global formal 
declaration on AMR calling for the development of action plans on AMR by both 
international and national bodies. The Global Action Plan on Antimicrobial 
Resistance was approved in May 2015 by the World Health Assembly with the key 
strategies to increase global AMR awareness as well as developing policies that will 
attract more investment in the area of new medical interventions [72]. There is also 
a call to all Member States for establishing National Action Plans for AMR by 2017 
of which about 57 countries have formalized such plans so far. The 2016 meeting 
of the UN General Assembly was another milestone focusing on multidisciplinary 
solution to the problems of AMR [73]. Moreover, the G20 called for the creation 
of a Global Research and Development (R&D) Collaboration Hub on AMR in July 
2017 that could coordinate international funding efforts [74], and the search for 
the appropriate individuals to lead that hub began early this year. In line with the 
global agreement to develop National Action Plan on AMR, Nigeria (with some 
other developing nations) keyed into this agreement in 2017 through a ‘One Health’ 
approach [75] and then enrolled into a Global Antimicrobial Resistance Surveillance 
System (GLASS). The Action Plan addresses five strategic objectives:
1. improving awareness and understanding of AMR through effective communi-
cation, education, and training
2. strengthening the knowledge and evidence base through surveillance and 
research
3. reducing the incidence of infection through effective sanitation, hygiene, and 
preventive measures
4. optimizing the use of antibiotics in human and animal health
5. preparing the economic case for sustainable investment and increasing invest-
ment in new medicine, diagnostic tools, vaccines, and other interventions
Several challenges exist regarding AMR containment in developing country like 
Nigeria; however, the development of this action plan is an important positive step 
in the right direction as it aims to address the problem at all level of governance and 
society [75].
Veterinarians play an important role in limiting and minimizing the spread of 
antimicrobial resistance (AMR). Because vets are often the first point of contact for 
livestock owners seeking animal medical attention, they can therefore play a part in 
addressing the problem of AMR [45]. One of the ways to reduce the risk of transfer of 
AMR from animals to humans is by minimizing the zoonotic transfer of bacteria [76]. 
This could be achieved by practicing stringent hygiene in the farms and any meat pro-
cessing plants including the abattoirs and the markets. Thorough and effective cooking 
of meat product can also reduce the risk of AMR [77]. There is need to strengthen the 
information resources in developing countries to support health workers, patients, 
animal owners, and attendants as well as the general public to help in reducing the risk 
of AMR arising from the use of antimicrobials in animals. This will enable the society to 
better understand the importance and value of antimicrobials. The excessive and inap-
propriate use of antimicrobials in veterinary practice should be discouraged. Because 
antimicrobials are an extremely valuable resource in livestock production, their prudent 
use in animals will continue to provide benefits to society and will help ensure high 
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standards of welfare for those animals in the care of veterinarians [78]. Since exposure 
of bacteria to subtherapeutic concentrations of antimicrobials is thought to increase 
the speed of the selection of resistance, this should always be avoided [14, 15, 79]. 
Appropriate pharmacokinetic and pharmacodynamic relations for antimicrobials used 
in animals should be developed [12]. Optimal dosage strategies for eliminating zoonotic 
organisms in animals will reduce the risk of transferring resistance to humans [80].
According to Delia [34], broad consensus on the management of AMR in human 
and animal healthcare will require to:
• reduce antibiotic use in humans and animals through public health improve-
ment such as hygiene and sanitation, immunization, infection control, as well 
as good housing and environment.
• regulate the sale and use of antibiotics through prescription.
• encourage research and development of new antimicrobials.
• minimize the level of environmental contamination of antimicrobials emanating 
from manufacturing process as well as agricultural, hospital, and community use.
• develop integrated global policies on the use of antibiotics.
• ban the nontherapeutic use of antimicrobials as growth promoters in agriculture.
Currently, there is no adequate information on animal production losses due to 
disease burden and the extent at which it could be prevented through proper use of 
antibiotics or their alternatives.
Although in Europe and other developed nations, the use of alternatives to 
antimicrobials as growth promoters is a success; their applicability in developing 
countries is not fully understood.
Despite the huge investments in the control of diseases in developing countries 
through vaccination, vector control, and the use of resistant breeds, evaluation 
from the angle of reduction in the usage of veterinary drug is lacking. In developing 
countries, the incidence and composition of substandard and fake drugs as well as 
their effects on treatment failure and resistance development is not well known. 
Similarly, the level of resilience of livestock farmers in developing countries to ban 
or restrict access to antimicrobials is equally not well known. It should be noted that 
policy and regulation alone is unlikely to improve use of vet drugs and the options 
for improving the use of vet drugs in agriculture and their effectiveness, feasibility, 
and affordability are not well understood.
4.1 Rational drug use
There have been success factors in the improvement of drug use in human 
health through wide range of intervention studies. Similarly, the World Animal 
Health Organization (OIE) and other world veterinary bodies also developed 
frameworks on rational use of vet drugs to which there is a limit veterinarians 
can make profit from antimicrobial sale for food animal production [71]. This is 
not the case in developing countries where the sale and use of veterinary antimi-
crobials is facing challenges for improvement. It was found from series of inter-
vention studies that training remains the most common strategy for improving 
drug use, but this gave little success unless when combined with other strategies 
like changing the market condition [1].
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4.2 Governance of antimicrobial use
Antimicrobial use in human and veterinary practice requires holistic approach 
in order to improve drug governance. There is need to list the critical or essen-
tial drugs in human and veterinary practice with requirement for prescription 
and guidelines such as banning the use of medically important antibiotics in 
agricultural practice and off-label use of antimicrobials as well as monitoring 
antimicrobial use and resistance. Not much success has been recorded in this 
regard in developing countries especially in livestock production and aquaculture 
due to little investments. According to OIE, better governance of veterinary 
antimicrobials comes from empowering veterinarians and limiting prescription 
to them. Most of the private veterinary service providers in developing countries 
are not operating at a significant scale and as such are often employed directly by 
agriculture and agro-allied companies making them to be less independent. The 
few that are successful are not operating with the guidelines of current OIE policy 
[81]. The community animal health workers (CAHWs), that have proven to be 
effective, are very expensive to train and may not be politically acceptable [82]. 
This is because there is lack of resources to support them by public veterinary 
services, and the private veterinarians often see them as potential competitors. 
A study investigated rational drug use by farmers and found that farmers in West 
Africa were mainly responsible for buying and using antimicrobials, and provid-
ing simple information on correct drug use could lead to improved drug usage 
as well as reduced amount of underdosages, which is an important factor for the 
development of AMR [83].
4.3 Antimicrobial alternatives in veterinary practice
As previously mentioned, developed countries banned the use of medically 
important antibiotics as well as growth promoters in animal production, which 
has led to better farming practices as well as reduction in AMR of medically 
important microbes found in farm animals. With this natural experiment, it 
demonstrated that routine antimicrobial usage is not a precondition for healthy 
animals as long as there is better hygiene and sanitation with good housing 
condition, and the use of antibiotics is only limited to clinical condition. The 
benefit of antimicrobials as growth promoters may sound reasonable only under 
poor management and hygiene situations [71]. Although the type of intensive 
livestock production in developing countries makes them rely more on nonthera-
peutic use of antimicrobials, there are many other promising innovations that 
could support profitable and productive agriculture with less reliance on antimi-
crobials use such as:
• The use of nonantibiotic growth promoters like enzymes in feed, competitive 
exclusion products as well as probiotics and prebiotics
• The use of other animal health technologies such as vaccines, vector control, 
disinfectants, phyto-therapy, as well as phage-therapy, which are underutilized 
in developing countries. The phage products can readily be designed to thwart 
development of resistance. They have been used as antibacterial agents for nearly 
100 years in the former Soviet Union, and they are now undergoing a renaissance 
in other countries due to the growing AMR problem [33, 84–87].
• The use of robust diagnostic techniques for improved drug selection and 
identification of AMR pathogens
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• The management and bio-security innovations like all-in-all-out systems, 
pathogen-free systems, stocking density reduction, and improved waste manage-
ment systems.
• The use of genetically disease resistant animals as well as avoidance of monocul-
tures of genetically similar animals.
All these intervention strategies will improve animal welfare as well as reducing 
environmental externalities of animal agriculture. A more radical suggestion is to 
decrease the amount of consumption of animal source food or shift from intensive 
to organic animal production.
5. Veterinary antimicrobial stewardship in developing countries
The safeguarding of antimicrobial agents for future generations is of utmost 
priority as AMR threatens the very core of modern medicines and the sustainability 
of an effective, global public health response to the enduring threats from infectious 
diseases [72]. In many developing countries of the world, gaps exist among health 
care professionals on the current status of antibiotic resistance in their area due to 
lack of a systematic surveillance at country, provincial, and district level [88]. There 
is a paucity of clinical data on antibiotic resistance, and this is particularly the case 
in resource-poor settings. Tons of antibiotics are used annually in clinical and agri-
cultural settings worldwide. The estimates of the total annual global consumption 
of antimicrobials in animal production vary considerably due to poor surveillance 
and data collection in many countries [89]. In 2013, food animals alone consumed 
over 130,000 tons of antibiotics [90]. It cannot be ignored that two-thirds of the 
estimated future growth of usage of antimicrobials is estimated to be within the 
animal production sector, with use in pig and poultry production predicted to 
double [89]. Nigeria, Pakistan, India, Bangladesh, China, and Egypt are the devel-
oping countries with massive consumption of antibiotics [88].
The implementation of rational and restricted use of antibiotics is lacking in most 
developing countries where you have the largest market of antimicrobial drugs and 
reports of the highest rate of antibiotic resistance [86, 87]. Due to these developments, 
antimicrobial stewardship programs have emerged as an essential means to attenuate 
the threat of a real possibility of the specter of a “postantibiotic era” [91, 92].
Antimicrobial stewardship is a harmonized program (the optimal selection, 
dosage, and drug regimen) that fosters the proper use of antimicrobials (includ-
ing antibiotics) with the goal of optimizing clinical outcomes, reducing microbial 
resistance, and lessening the spread of infections produced by multidrug-resistant 
organisms. The main objectives of antimicrobial stewardship are to attain excellent 
patient outcomes associated with antimicrobial use while reducing toxicity and 
other unfavorable events, thereby curbing the discriminatory pressure on bacterial 
population that propels the emergence of multidrug-resistant strains [93, 94].
Antimicrobial stewardship programs (ASPs) are a cornerstone of the response to 
the AMR crisis in human medicine but are still largely underdeveloped in veterinary 
medicine [95]. Antimicrobial stewardship is important to both animal health and 
food safety. Just like humans, animals get infections that require treatment with anti-
biotics. The rise of antimicrobial resistance is a serious threat to public health [30]. 
It is imperative that antibiotic stewardship programs seeking to preserve the effec-
tiveness of existing antibiotics in human health also consider strategies that reduce 
overuse of antibiotics in the agricultural sector as antimicrobials are used in terrestrial 
animal production practices to preserve animal and public health, but also as growth 
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promoters at a subtherapeutic level [89]. Other aspects to be considered with regard 
to antimicrobial use include the distinction between therapeutic and nontherapeutic 
use, between the diverse existing production systems and between specifics related to 
the different animal species and their eco-geographical location [72, 89].
According to the WHO, FAO, and OIE global tripartite database for antimi-
crobial resistance country self-assessment in 2016–2017, 42% of the countries on 
question regarding antimicrobial stewardship and regulation in animals and crop 
production responded that no national policy or legislation regarding the quality 
and efficacy of antimicrobials and their use in animals, and crops was available [101]. 
Responses to other veterinary-related questions showed a huge gap in the prepared-
ness for combating AMR and also the lack of policy making and implementation of 
a successful antimicrobial stewardship program.
Various strategies have been shown to improve appropriateness of antimicrobial 
use and cure rates, decrease failure rates, and reduce healthcare-related costs in 
human hospitals [96–98]. According to Guardabassi & Prescott [95], the following 
successful strategies used in human hospitals can be adopted with focus on their 
implementation in veterinary practice.
• educational approaches
• development and implementation of guidelines
• preprescription approval
• postprescription review
• computer-based decision support
It should be noted that one strategy does not exclude the other and that multiple 
strategies can be successfully used in combination.
A good antimicrobial stewardship program (ASP) needs remarkable input 
in research and training by all stakeholders including national and international 
veterinary organizations, funding concerns, and animal health industries [95]. 
At governmental levels, the growth and execution of ASPs need coordination of 
the task of national public health and veterinary authorities, veterinary clinics, 
organizations, and private practitioners. The concept of antimicrobial stewardship 
and of its continuous improvement is in its relative infancy in various sectors of 
veterinary practice in developing countries, but every veterinary component of the 
agricultural sector has the responsibility and access to a wide range of resources to 
develop an ASP.
Stewardship of antimicrobial drugs in human healthcare and veterinary set-
tings is essential to slow the emergence of resistance and extending the useful life 
of effective antimicrobials according to FDA Center for Veterinary Medicine [99]. 
All developing countries should be committed to advancing efforts to implement 
good antimicrobial stewardship practices in veterinary settings as part of their role 
to protect human and animal health. Each program must be region-specific and 
constantly under review given that resistance patterns change, requiring changes to 
local policy of, for example, empirical antibiotic choice [100].
Therefore, the goals in all countries should be to align antimicrobial drug 
product use with the principles of antimicrobial stewardship, foster antimicrobial 
stewardship in veterinary settings, and enhance monitoring of antimicrobial resis-
tance and use in animals to further preserve antimicrobial drugs to ensure human 
and animal health [99].
13
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Veterinary Pharmaceuticals and Antimicrobial Resistance in Developing Countries
DOI: http://dx.doi.org/10.5772/intechopen.84888
6. Conclusion and recommendation
Resistance to antimicrobial agents arises in some instance through excessive 
use in animals as chemotherapeutics, and as subtherapeutic additives in feeds. 
Prolong exposure of microorganisms to sublethal doses of antimicrobials can result 
in spontaneous emergence of resistance gene and its subsequent transfer among 
animals, environment and animal products in food chain, and transfer of resistance 
to human. A pragmatic approach to slow down the development of antimicrobial 
resistance is to control abuse of antimicrobials through a number of measures. First, 
it is important to recognize that veterinary pharmaceuticals are important beyond 
animals and include human health and the environment, hence the need for “One 
Health” guidiance and regulation. Secondly, it is necessary to reduce drugs that are 
used as prophylaxis and should rather improve research and innovation for vaccine 
development, application and explore other alternatives to chemotherapies. The 
use of feed grade antibiotics and additives in feed as growth promoters also need to 
be discouraged in developing countries and instead promote organic, home grown 
livestock husbandry to complement intensive and factory farming. Alternatives to 
growth-promoting and prophylactic uses of antimicrobials in agriculture include 
improved management practices, wider use of vaccines, probiotics, and phage virus. 
Monitoring programs, prudent usage that are controlled, and educational campaigns 
are some of the approaches that can minimize further development of antimicrobial 
resistance in developing countries especially. These can be achieved through mutual 
and ‘One Health’ understanding of the challenges and informed solution through 
antibiotic stewardship by promoting collective action of all parties with interest 
including producers, consumers, and mediators.
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